Identification of Differently Expressed Genes Associated With Prognosis and Growth in Colon Adenocarcinoma Based on Integrated Bioinformatics Analysis

Hu, Ming; Fu, Xiandong; Si, Zhaoming; Li, Chunming; Sun, Jihu; Du, Xinna; Zhang, Hu

doi:10.3389/fgene.2019.01245

Cited by 39 publications

(33 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 16 ] In a study on colon adenocarcinoma, it was also reported that high expression of the CCT6A promoted tumor cell growth, and was also associated with low survival rate of such patients. [ 12 ] CCT6A has also reported to be strongly association with survival and prognosis in renal cancer, with patients with altered CCT6A mRNA (stage I-IV) having significantly shorter OS compared to healthy controls. [ 4 ] Thus, the CCT6A gene plays a key role in the development and prognosis prediction of many tumors.…”

Section: Discussionmentioning

confidence: 99%

CCT6A, a novel prognostic biomarker for Ewing sarcoma

Jiang

Liu

et al. 2021

Medicine

View full text Add to dashboard Cite

Background: Ewing sarcoma (ES), the second most prevalent bone malignant tumor has no widely known prognostic biomarker. Earlier studies have suggested that chaperonin containing TCP1 complex 6A (CCT6A), which encodes a molecular protein chaperone, is involved in the pathogenesis of many cancers. However, there are no known reports providing clear evidence of its role in ES pathogenesis. Methods: We performed a bioinformatic analysis of 32 ES specimens from the GSE17618 dataset concentrating on the differences in gene expression, OS, event-free survival (EFS) in the different subgroups. Immunohistochemical studies were also performed to identify the expression levels of selected genes in ES and immediate paracancerous tissues. Results: After 3 screenings, CCT6A was identified to be highly correlated with ES prognosis. Our survival analysis revealed a low overall survival (OS) for high CCT6A expression ( P -value = .024). Our Cox regression analysis identified CCT6A expression, lEFS, and age were strongly associated with prognosis of ES. Our multivariate Cox regression analysis shows that CCT6A ( P -value = .015), age ( P -value = .026), and EFS ( P -value = .002) were independent poor prognostic biomarkers. Our immunohistochemical analysis showed that the expression levels of CCT6A were significantly higher in ES tissues compared to the paracancerous tissues. Conclusion: From the results of our study, we identified the expression levels of CCT6A to be strongly associated with prognosis of ES. Thus, the expression levels of the CCT6A gene could serve as a biomarker for the prediction of ES prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

CCT6A, a novel prognostic biomarker for Ewing sarcoma

Jiang

Liu

et al. 2021

Medicine

View full text Add to dashboard Cite

show abstract

“…The pathophysiological processes regulated by these genes were closely related to tumors. The high expression of DDOST in colon adenocarcinoma promotes the proliferation of tumor cells [20]. The expression of RCC2 in ER-positive breast induces the expression of IGF-1 and leads to the malignant behavior of tumor cells, including proliferation, invasion, etc.…”

Section: Discussionmentioning

confidence: 99%

The increasing expression of GPX7 related to the malignant clinical features leading to poor prognosis of glioma patients

et al. 2021

View full text Add to dashboard Cite

Background Glioma is the most common malignant brain tumor in adults. The standard treatment scheme of glioma is surgical resection combined alternative radio- and chemotherapy. However, the outcome of glioma patients was unsatisfied. Here, we aimed to explore the molecular and biological function characteristics of GPX7 in glioma. Methods The multidimensional data of glioma samples were downloaded from Chinese Glioma Genome Atlas (CGGA). RT-qPCR method was used to identify the expression status of GPX7. Kaplan–Meier curves and Cox regression analysis were used to explore the prognostic value of GPX7. Gene Set Enrichment Analysis (GSEA) was applied to investigate the GPX7-related functions in glioma. Results The results indicated that the expression of GPX7 in glioma was higher compared to that in normal brain tissue. Univariate and multivariate Cox regression analyses confirmed that the expression value of GPX7 was an independent prognostic factor in glioma. The GSEA analysis showed that GPX7 was significantly enriched in the cell cycle pathway, ECM pathway, focal adhesion pathway, and toll-like receptor pathway. Conclusions The GPX7 was recommended as an independent risk factor for patients diagnosed with glioma for the first time and GPX7 could be potentially used as the therapy target in future. Furthermore, we attempted to explore a potential biomarker for improving the diagnosis and prognosis of patients with glioma.

show abstract

“…Klimczak M used the TCGA database to identify the overexpression of CCT6A in breast cancer as a signi cant contributor to poor prognosis [21] . In a study on colon adenocarcinoma, it was pointed out that high expression of the CCT6A promoted the growth of colon adenocarcinoma cells on the one hand, and was associated with low survival rate of colon adenocarcinoma on the other [22] . CCT6A also showed a strong association with survival and prognosis in renal cancer, with patients with altered CCT6A mRNA (stage I-IV) having signi cantly shorter overall survival compared to healthy controls [23] .…”

Section: Discussionmentioning

confidence: 99%

CCT6A, a novel prognostic biomarker for Ewing's sarcoma

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Ewing's sarcoma (ES) is the second most prevalent malignancy among bone tissue tumors, and there is no adequate prognosis biomarker. The protein encoded by CCT6A is a molecular chaperone. Early studies have suggested that CCT6A is involved in the development of many cancers, however, there is no clear evidence of a role for CCT6A in ES. Methods In this study, we performed a bioinformatics analysis of 32 Ewing sarcoma specimens from the GSE17618 dataset for differences in gene expression and overall survival, event-free survival, and gene expression in different subgroups. Results After three screenings, we identified CCT6A as highly correlated with Ewing's sarcoma prognosis. Survival analysis showed low overall survival (OS) for CCT6A high expression (P = 0.024). On the other hand, Cox regression analysis showed that CCT6A expression, event-free survival (EFS), and age were strongly associated with the prognosis of Ewing sarcoma, identified as independent poor prognostic biomarkers. (CCT6A: P = 0.015; Age: P-value = 0.026; EFS: P-value = 0.001). Conclusion The expression level of CCT6A is strongly associated with the prognosis of Ewing's sarcoma. High expression of the CCT6A gene may serve as a biomarker for poor prognosis in patients with Ewing's sarcoma.

show abstract

Identification of Differently Expressed Genes Associated With Prognosis and Growth in Colon Adenocarcinoma Based on Integrated Bioinformatics Analysis

Cited by 39 publications

References 36 publications

CCT6A, a novel prognostic biomarker for Ewing sarcoma

CCT6A, a novel prognostic biomarker for Ewing sarcoma

The increasing expression of GPX7 related to the malignant clinical features leading to poor prognosis of glioma patients

CCT6A, a novel prognostic biomarker for Ewing's sarcoma

Contact Info

Product

Resources

About